{"id":"ixekizumab-prefilled-syringe","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Injection site reactions"},{"rate":"10-15","effect":"Upper respiratory tract infections"},{"rate":"1-3","effect":"Candida infections (oral/esophageal)"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1743034","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-17A is a pro-inflammatory cytokine produced by T cells that plays a central role in the pathogenesis of autoimmune and inflammatory conditions. By blocking IL-17A, ixekizumab reduces the recruitment and activation of immune cells at sites of inflammation, thereby suppressing the inflammatory cascade. This mechanism is particularly effective in conditions driven by Th17 cell-mediated immunity, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.","oneSentence":"Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:39.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Non-radiographic axial spondyloarthritis"}]},"trialDetails":[{"nctId":"NCT06085079","phase":"PHASE4","title":"Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study","status":"UNKNOWN","sponsor":"Massachusetts Eye Research and Surgery Institution","startDate":"2022-06-01","conditions":"Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate","enrollment":20},{"nctId":"NCT03848403","phase":"PHASE1","title":"Study of Ixekizumab in Healthy Participants","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2019-01-29","conditions":"Healthy","enrollment":70},{"nctId":"NCT03848416","phase":"PHASE1","title":"A Study of Ixekizumab in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-01-29","conditions":"Healthy","enrollment":99},{"nctId":"NCT01777191","phase":"PHASE3","title":"Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-03","conditions":"Plaque Psoriasis","enrollment":204}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY2439821"],"phase":"marketed","status":"active","brandName":"Ixekizumab Prefilled Syringe","genericName":"Ixekizumab Prefilled Syringe","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}